Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure (NCT00701038), a randomized na study. The primary outcome is Left Ventricular Ejection Fraction Improvement.

2. Clinical Question

The trial addresses the role of sleep-apnea diagnosis and treatment during acute heart failure hospitalization. Its posted primary outcome concerns left ventricular function, assessed using Doppler ultrasound. The registry record does not report a sleep-apnea diagnostic outcome, so the posted result does not establish how often sleep apnea was identified or whether the device was used only by participants with a particular sleep-apnea status.

3. Trial Design

The registry describes a randomized, parallel-group trial with no masking. One arm received an auto-adjusting bi-level positive airway pressure device, and the control arm received no device. The enrollment is listed as 54. The registry lists the study as completed, with a start date of 2006-08 and primary completion date of 2008-08. The phase is listed as NA.

The primary outcome is labeled as an intention-to-treat population. The posted outcome summaries list 23 participants in the device arm and 23 in the control arm. These outcome counts do not match the enrollment figure; the reason for the difference is not reported in the registry record. The safety record separately lists 27 participants at risk in each arm. The record does not explain how the outcome, enrollment, and safety populations relate to one another, so these counts should not be treated as interchangeable.

The primary outcome was measured at baseline and again after three nights in hospital. The record reports one primary outcome and no posted secondary outcomes. It does not describe the randomization procedure, concealment of allocation, masking of outcome assessors, device-use adherence, or the details of other care during hospitalization. It also does not report the trial's original sample-size assumptions or statistical analysis plan. The trial design therefore establishes the broad randomized comparison, but not all operational details needed to assess how the comparison was conducted.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: ITT

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Left Ventricular Ejection Fraction Improvement, measured over baseline and again after three nights in hospital.

The primary endpoint is titled “Left Ventricular Ejection Fraction Improvement.” It measures percent change in left ventricular function from baseline to the assessment after three nights in hospital. Function was assessed using Doppler ultrasound. The registry identifies the outcome as continuous and reports the mean for each arm, with standard errors as the measure of dispersion.

As a general statistical point, a continuous measurement retains information about the magnitude of a participant's result rather than reducing it to a yes-or-no category. Comparing arm means can therefore describe the average difference in change between the randomized groups. A positive increase from baseline is described in the registry as indicating a potential beneficial impact on heart function, but the endpoint itself is a surrogate measure: it is not a count of deaths, hospital readmissions, symptoms, or other patient-centered events.

The posted means are 4.5 for the device arm and -0.3 for the control arm, in percent change. The reported mean difference is 4.8. These values describe the posted short-term outcome. The registry does not report further measurement details, such as ultrasound reading procedures, assessor reliability, or how measurements were handled when a follow-up assessment was unavailable.

7. Results Posted in the Registry

• Device: mean 4.50 versus -0.30 on control; difference 4.80 (95% CI 0.36 to 9.24), standardized effect d = 0.62; z-test p = 0.034.

8. Statistical Interpretation

9. Statistical Methods Explained

What does a mean difference describe?

As a general statistical explanation, a mean difference compares the average outcome in one group with the average outcome in another. Here, the registry reports a mean difference of 4.8 in percent change, with the device-arm mean higher than the control-arm mean. The result is expressed on the scale of the outcome. It is not a relative percentage increase, a ratio, or a count of participants who improved.

The group summaries report means of 4.5 for the device arm and -0.3 for the control arm. Those are averages, so they do not describe each participant's result. A mean can be influenced by unusually high or low observations, and the registry record does not provide distributions, medians, or individual observations for examining that possibility.

What do the standard errors tell the reader?

The registry reports standard errors of 1.7 for the device-arm mean and 1.5 for the control-arm mean. As a general statistical explanation, a standard error describes the sampling uncertainty of an estimated mean. It is not the standard deviation of individual outcomes. A standard deviation describes variation among observations; a standard error concerns the precision of an estimate and is affected by both variability and the amount of information contributing to that estimate.

The record also reports a pooled standard deviation of 7.688 in the comparison details. A pooled standard deviation combines information about within-group spread under a particular summary approach. The registry does not explain the calculation method beyond listing this value. It should not be confused with either of the arm-specific standard errors.

What does the interval contribute?

As a general statistical explanation, an interval around an estimate represents a range of values compatible with the data under a specified method and its assumptions. Wider intervals indicate less precision than narrower intervals on the same scale. The registry comparison reports an interval with a positive lower endpoint and an upper endpoint of 9.244. The lower endpoint's exact value is not repeated; the confidence level and interval construction are not reported in the registry record. Without those details, the interval can be described, but its precise coverage interpretation cannot be verified from the record.

An interval is useful alongside a point estimate because it makes uncertainty visible. The point estimate of 4.8 is not an exact description of the underlying difference. The interval indicates a range of compatible values, but it does not show the probability that a particular value is true, and it does not account for every possible source of bias or design limitation.

How should the p value be understood?

The reported p value is unadjusted and equals 0.034. As a general statistical explanation, a p value evaluates the compatibility of the observed data with a specified null model, conditional on the test and its assumptions. Smaller values indicate that the data would be less expected under that null model. A p value is not an effect-size measure, does not quantify clinical importance, and is not the probability that the result occurred by chance.

The registry does not identify the statistical test, its assumptions, or whether the comparison used any adjustment for baseline measures. It also does not state the trial's own significance threshold. A significance level of 0.05 appears among the assumptions for the separate planning illustration, but those planning assumptions are not evidence of the trial's original analysis plan.

What can randomization and masking tell us?

As a general statistical explanation, random assignment is intended to make treatment groups comparable on average, including for factors that are not measured. It supports interpretation of a between-group contrast, subject to the conduct of the trial and the completeness of follow-up. The registry identifies the allocation as randomized and the model as parallel. It does not report how the sequence was generated or concealed, so those safeguards cannot be assessed from the registry record.

Masking is listed as none. As a general matter, lack of masking can influence treatment behavior, co-interventions, outcome assessment, and reporting, depending on the outcome and trial procedures. The record does not say whether outcome assessors were masked independently of participants and study staff. Since the endpoint involves an ultrasound assessment, that missing detail limits assessment of how the measurement process may have been protected from knowledge of assignment.

What does the intention-to-treat label mean?

As a general statistical explanation, an intention-to-treat analysis aims to analyze participants according to their randomized assignment, regardless of the treatment actually received. The primary outcome is labeled ITT in the registry. However, the registry does not explain the analysis population in detail or how missing outcomes and treatment deviations were handled. The listed outcome summaries include 23 participants per arm. The reason those counts differ from enrollment and safety counts is not reported in the registry record. The ITT label alone does not resolve those questions.

10. Confidence Intervals and Precision

The mean difference is reported as 4.8, and the comparison interval has a positive lower endpoint and an upper endpoint of 9.244. The interval therefore does not include zero. The exact lower endpoint is not repeated because the registry reports it with more than three decimal places. The confidence level and method used to construct the interval are not reported in the registry record.

As a general statistical explanation, the width of an interval conveys precision: a narrower interval indicates a more tightly estimated value, while a wider interval leaves more uncertainty about the plausible magnitude. The posted interval permits a range of positive mean differences, so the point estimate should not be treated as exact. Its upper endpoint is appreciably higher than the point estimate, indicating that larger values remain compatible with the reported interval as well.

The arm-level standard errors are 1.7 for the device mean and 1.5 for the control mean. These quantify uncertainty in the means, not the full spread of participant-level results. The record does not give a standard deviation for each arm, a confidence interval for either arm mean, or a distribution of individual changes. The pooled standard deviation is 7.688, but it does not substitute for a complete account of the outcome distribution.

Precision also depends on which participants contribute outcome data and how missing values are treated. The outcome summaries list 23 participants per arm, while the registry lists enrollment as 54 and safety at-risk counts of 27 per arm. The explanation for these counts and any missing-outcome procedure are not reported in the registry record. The interval describes statistical uncertainty under its method; it does not incorporate uncertainty about those unreported design and analysis details.

11. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size planning figures are participants per arm, not total events. They are illustrative planning values based on the observed mean difference, rather than the trial's own original design assumptions. The listed assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. Each planning row considers an effect to detect expressed as a fraction of the observed effect.

The 80% power column describes the participants per arm indicated by the planning calculation for an 80% chance of detecting the specified effect under those assumptions, if that effect and the assumptions were correct. The 90% power column gives the corresponding per-arm planning figure for a 90% chance. These are design calculations, not guarantees that a future study will detect an effect.

The rows consider planning for 100% of the observed effect, 75% of the observed effect, and 50% of the observed effect. The listed figures are 41 and 54 participants per arm for the full observed effect; 72 and 96 for 75% of the observed effect; and 162 and 216 for 50% of the observed effect, with the 80% and 90% columns read in that order. Smaller effects require more participants to detect under the same planning assumptions.

This is not observed power. The trial's original sample-size justification and design assumptions are not reported in the registry record. The planning illustration should not be read as evidence that the completed trial had a particular probability of detecting its result, nor as a replacement for the trial's unreported design rationale.

12. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = 4.800; pooled standard deviation σ = 7.688.
2. n = 2 × (1.96 + 0.842)² × 7.688² / 4.800² = 40.3, rounded up to 41 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- 4.8                      # observed difference in means
sigma <- 7.68830280361017                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(701038)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 41 (80% power), 54 (90% power)
 75% of observed effect: n per arm = 72 (80% power), 96 (90% power)
 50% of observed effect: n per arm = 162 (80% power), 216 (90% power)
power.t.test: 41.3 
Simulated power at n = 41 per arm: 0.793 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

13. Multiplicity, Missing Data and Analysis Populations

The registry record lists one primary outcome and no posted secondary outcomes. It does not report a prespecified statistical analysis plan, the number of analyses conducted, or whether any interim analyses were planned or performed. Those details are not reported in the registry record, so the extent of any multiplicity considerations cannot be assessed.

As a general statistical explanation, multiplicity arises when multiple outcomes, time points, subgroups, or statistical tests are examined. Repeated testing can increase the chance of finding an apparently unusual result even when no real difference exists. Methods such as prespecification or adjustment can address some multiplicity concerns, but the registry does not report whether such methods were used. The posted p value is explicitly unadjusted.

The primary outcome is labeled as intention-to-treat, but the handling of missing outcome measurements is not reported in the registry record. The record does not say whether all assigned participants had ultrasound measurements at follow-up, whether any values were imputed, or how participants without follow-up measurements were treated in the analysis. The outcome summaries list 23 participants per arm, while the enrollment figure is 54. The reason for this difference is not reported.

The record also does not report a per-protocol analysis, adherence summaries, or sensitivity analyses addressing missing data or deviations from assignment. These omissions do not establish that such analyses or procedures were absent; they mean the registry record does not document them. Consequently, the effect of missingness, analysis choices, and any unreported multiplicity on the posted estimate cannot be determined from the recorded information.

14. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The safety record lists 27 participants at risk in each arm. It records zero serious adverse events and zero other adverse events in the device arm, and zero serious adverse events and zero other adverse events in the control arm. These are the event figures recorded for the listed at-risk groups; they should not be taken as proof that no adverse events could occur or that the risks were identical.

The death fields contain no reported counts. Death information is therefore not reported in the registry record. The record does not describe how adverse events were defined, how long safety events were monitored, how events were collected, or whether reporting covered all participants throughout the same period. It also does not explain why the at-risk counts differ from the outcome summaries. Those limitations matter when interpreting zero recorded events: the figures describe the registry entries, not a complete account of safety under every possible definition or follow-up approach.

15. What the Result Does, and Does Not, Mean

The posted data show a higher average percent change in left ventricular ejection fraction in the device arm than in the control arm over the assessment from baseline to after three nights in hospital. The reported mean difference is 4.8. The comparison interval has a positive lower endpoint and an upper endpoint of 9.244, and the unadjusted p value is 0.034. These figures describe the registry's short-term primary-outcome comparison.

They do not establish what happened to each participant. Group averages can conceal a wide range of individual results, and the registry record does not give individual measurements or full outcome distributions. The estimates also do not show whether the difference persisted beyond the posted assessment time. Longer-term outcomes, including death, readmission, symptoms, and quality of life, are not reported as outcomes in this record.

The result does not answer every question about sleep apnea in acute heart failure. The record does not report a sleep-apnea diagnostic result or a subgroup analysis by sleep-apnea status. It therefore cannot establish from the posted primary outcome how the result varies according to whether sleep apnea was present or diagnosed. The device-versus-no-device comparison also does not provide enough detail to characterize other care or the extent of device use.

As a general statistical point, a p value and an interval address uncertainty under a statistical model; neither demonstrates clinical importance or removes possible bias. The absence of masking, unreported details of randomization and outcome assessment, and unreported missing-data procedures limit how fully the comparison can be evaluated. The registry result is best interpreted as an estimate for this specific short-term endpoint, with the record's design and reporting limitations kept in view.

16. Why This Trial Matters Statistically

This trial is statistically notable for comparing a device strategy with no device using a continuous measure of heart function in a randomized, parallel-group design. The primary outcome is a change from baseline, and the reported mean difference preserves information about magnitude rather than reducing the endpoint to an event count. The comparison is accompanied by an interval and an unadjusted p value, allowing readers to consider both the estimated difference and its statistical uncertainty.

The record also illustrates why different kinds of uncertainty should be kept separate. The standard errors and comparison interval describe sampling precision under their methods. They do not resolve uncertainties about how the randomization was conducted, who assessed the ultrasound outcome, how missing measurements were handled, or whether the posted analysis followed a prespecified plan. Those details are not reported in the registry record.

Counts require careful interpretation as well. Enrollment is listed as 54, the outcome summaries list 23 participants in each arm, and the safety record lists 27 at risk in each arm. These figures refer to different registry entries, and the reason they differ is not reported. Treating them as if they described one identical analysis population would obscure an important reporting limitation.

Finally, the endpoint is measured after three nights in hospital. This narrow time frame makes the result a short-term comparison rather than an account of longer-term clinical outcomes. No secondary outcomes are posted. The distinction between a statistical signal on a surrogate measure and evidence about broader clinical outcomes is central to interpreting what this trial can establish.

17. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the information recorded for this trial. The study was unmasked, and the registry does not say whether outcome assessors were masked. Since the primary outcome was assessed using Doppler ultrasound, the lack of information about assessment procedures makes it difficult to judge how measurement was protected from possible knowledge of treatment assignment.

The outcome is measured after three nights in hospital, so the registry comparison is limited to a short-term endpoint. Longer-term follow-up and outcomes such as survival, readmission, symptoms, and quality of life are not reported. The registry also does not post a sleep-apnea diagnostic result or results by sleep-apnea status, despite the trial's focus on sleep apnea.

Population counts are not fully reconciled: enrollment is 54, the outcome summaries list 23 per arm, and the safety record lists 27 at risk per arm. The reason for these differences is not reported in the registry record. The primary outcome is labeled ITT, but missing-data handling, adherence, treatment deviations, and analysis-population details are not reported.

The registry does not give the statistical test, confidence level, analysis plan, original sample-size rationale, or details of randomization and allocation concealment. It also reports no secondary outcomes. These omissions limit independent assessment of the analysis and the robustness of the primary comparison; they should not be taken as proof that procedures were not used.

18. Related Tutorials

19. Related Statistical Calculators

20. Sources

• ClinicalTrials.gov: Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure — NCT00701038.
• Registry record last updated 2013-02-04; status last verified 2013-01.
• Results first posted 2011-12-14.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

21. Record Summary

The registry describes a completed, randomized, unmasked, parallel-group trial of an auto-adjusting bi-level positive airway pressure device versus no device in acute exacerbation of heart failure. Enrollment is listed as 54. The primary endpoint is mean percent change in left ventricular ejection fraction, assessed at baseline and after three nights in hospital, and labeled as an intention-to-treat outcome.

The posted arm means are 4.5 for the device group and -0.3 for control; the reported mean difference is 4.8, with an unadjusted p value of 0.034. The comparison interval has a positive lower endpoint and an upper endpoint of 9.244. No secondary outcomes are posted. The registry does not report the original sample-size rationale, confidence level, detailed analysis plan, or the reason enrollment, outcome, and safety counts differ.